[1]
Alberti, P.; Salvalaggio, A.; Argyriou, A.A.; Bruna, J.; Visentin, A.; Cavaletti, G.; Briani, C. Neurological complications of conventional and novel anticancer treatments. Cancers (Basel), 2022, 14(24), 6088.
[http://dx.doi.org/10.3390/cancers14246088]
[http://dx.doi.org/10.3390/cancers14246088]
[2]
Vaz-Luis, I.; Masiero, M.; Cavaletti, G.; Cervantes, A.; Chlebowski, R.T.; Curigliano, G.; Felip, E.; Ferreira, A.R.; Ganz, P.A.; He-garty, J.; Jeon, J.; Johansen, C.; Joly, F.; Jordan, K.; Koczwara, B.; Lagergren, P.; Lambertini, M.; Lenihan, D.; Linardou, H.; Loprinzi, C.; Partridge, A.H.; Rauh, S.; Steindorf, K.; van der Graaf, W.; van de Poll-Franse, L.; Pentheroudakis, G.; Peters, S.; Pravettoni, G. ESMO expert consensus statements on cancer survivorship: promoting high-quality survivorship care and research in Eu-rope. G. Ann. Oncol., 2022, 33(11), 1119-1133.
[http://dx.doi.org/10.1016/j.annonc.2022.07.1941]
[http://dx.doi.org/10.1016/j.annonc.2022.07.1941]
[3]
Alberti, P.; Bernasconi, D.P.; Cornblath, D.R.; Merkies, I.S.J.; Park, S.B. Velasco, R.; Bruna, J.; Psimaras, D.; Koeppen, S.; Pace, A.; Dorsey, S.G.; Argyriou, A.A.; Kalofonos, H.P.; Briani C, Schenone A, Faber CG, Mazzeo A, Grisold W, Valsecchi M, Cavaletti G; CI-PeriNomS, group. Prospective evaluation of health care provider and patient assessments in chemotherapyinduced peripheral neurotoxicity. Neurology, 2021, 97(7), e660-e672.
[http://dx.doi.org/10.1212/WNL.0000000000012300]
[http://dx.doi.org/10.1212/WNL.0000000000012300]
[4]
Fumagalli, G.; Monza, L.; Cavaletti, G.; Rigolio, R.; Meregalli, C. Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. Front. Immunol., 2021, 4(11), 626687.
[http://dx.doi.org/10.3389/fimmu.2020.626687]
[http://dx.doi.org/10.3389/fimmu.2020.626687]
[5]
Pero, M.E.; Meregalli, C.; Qu, X.; Shin, G.J.; Kumar, A.; Shorey, M.; Rolls, M.M.; Tanji, K.; Brannagan, T.H.; Alberti, P.; Fumagalli, G.; Monza, L.; Grueber, W.B.; Cavaletti, G.; Bartolini, F. Pathogenic role of delta 2 tubulin in bortezomibinduced peripheral neuropathy. Proc. Natl. Acad. Sci. USA, 2021, 118(4), e2012685118.
[http://dx.doi.org/10.1073/pnas.2012685118]
[http://dx.doi.org/10.1073/pnas.2012685118]
[6]
Fontana, D.; Mauri, M.; Renso, R.; Docci, M.; Crespiatico, I.; Røst, L.M.; Jang, M.; Niro, A.; D’Aliberti, D.; Massimino, L.; Bertagna, M.; Zambrotta, G.; Bossi, M.; Citterio, S.; Crescenzi, B.; Fanelli, F.; Cassina, V.; Corti, R.; Salerno, D.; Nardo, L.; Chinello, C.; Mantegazza, F.; Mecucci, C.; Magni, F. Cava-letti G, Bruheim P, Rea D, Larsen S, GambacortiPasserini C, Piazza R. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nat. Commun., 2020, 11(1), 5938.
[http://dx.doi.org/10.1038/s41467-020-19721]
[http://dx.doi.org/10.1038/s41467-020-19721]
[7]
Pozzi, E.; Fumagalli, G.; Chiorazzi, A.; Canta, A.; Meregalli, C.; Monza, L.; Carozzi, V.A.; Oggio-ni, N.; Rodriguez-Menendez, V.; Cavaletti, G.; Marmiroli, P. The relevance of multimodal assessment in ex-perimental oxaliplatin-induced peripheral neurotoxicity. Exp. Neurol., 2020, 334, 113458.
[http://dx.doi.org/10.1016/j.expneurol.2020.113458]
[http://dx.doi.org/10.1016/j.expneurol.2020.113458]
[8]
Jordan, B.; Margulies, A.; Cardoso, F.; Cavaletti, G.; Haugnes, H.S.; Jahn, P.; Le Rhun, E.; Preusser, M.; Scotté, F.; Taphoorn, M.J.B.; Jordan, K. ESMO guidelines committee. Systemic anticancer therapyinduced peripheral and central neurotoxicity: esmo-eons-eano clin-ical practice guidelines for diagnosis, prevention, treatment and followup. Ann. Oncol., 2020, 31(10), 1306-1319.
[http://dx.doi.org/10.1016/j.annonc.2020.07.003]
[http://dx.doi.org/10.1016/j.annonc.2020.07.003]
[9]
Loprinzi, C.L.; Lacchetti, C. Bleeker. J.; Cavaletti, G.; Chauhan, C.; Hertz, D.L.; Kelley, M.R.; Lavino, A.; Lustberg, M.B. Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and management of chemother-apy-induced peripheral neuropathy in survivors of adult cancers: asco guideline update. J. Clin. Oncol., 2020, 38(28), 3325-3348.
[http://dx.doi.org/10.1200/JCO.20.01399]
[http://dx.doi.org/10.1200/JCO.20.01399]
[10]
Huang, K.M.; Leblanc, A.F.; Uddin, M.E.; Kim, J.Y. Chen. M.; Eisenmann, E.D.; Gibson, A.A.; Li, Y.; Hong, K.W.; DiGiacomo, D.; Xia, S.H.; Alberti, P.; Chiorazzi, A.; Housley, S.N.; Cope, T.C.; Sprowl, J.A.; Wang, J.; Loprinzi, C.L.; Noonan, A.; Lustberg, M.B.; Cavaletti, G.; Pabla, N.; Hu, S.; Sparreboom, A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J. Clin. Invest., 2020, 130(9), 4601-4606.
[http://dx.doi.org/10.1172/JCI136796] [PMID: 32484793]
[http://dx.doi.org/10.1172/JCI136796] [PMID: 32484793]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
